CTC isolation and biomarker profiling of 193 advanced lung cancer (ALC) patients using the DCGI-approved OncoDiscover® EpCAM-targeted immunomagnetic nanoparticle platform
CTCs detected in 67% of patients (n=129), with a mean CTC value of 4.2; 33% showed absence of CTCs, potentially linked to therapy response or low CTC shedding
PD-L1 expression detected in 66% of CTC-positive patients (n=85), assessed via automated immunofluorescence using anti-PD-L1 monoclonal antibodies
EGFR expression identified in 34% of CTC-positive patients (n=44), with strong expression signals compared to tissue biopsy literature benchmarks
Fluorescence microscopy images show CTC identification (CK18+, CD45−, DAPI+) and functional assays for PD-L1 and EGFR co-expression on captured CTCs
Liquid biopsy advantage highlighted over tissue biopsy for real-time, dynamic monitoring of actionable oncogenic targets and immune checkpoint biomarkers in progressive disease